PDF(Sci-hub)
Abstract：
Human leukocyte antigen G (HLA-G) is a non-classical HLA class I molecule involved in inducing tolerance at the feto-maternal interface and in escape of immune response by tumor cells. The aim of the study is to review the published literature on the expression of HLA-G in malignant melanomas and its clinicopathological and prognostic correlates.
A systematic search was carried out in electronic databases. Studies dealing with HLA-G expression in surgically-removed human samples were retrieved and analyzed.
Of 1737 retrieved articles, 16 were included. The main themes regarded HLA-G expression in malignant melanocytic lesions, assessed by immunohistochemistry (IHC), soluble or molecular techniques, and its relationship with clinicopathological features, such as tumor thickness and malignant behavior. Overall significant HLA-G expression was found in 460/843 tumors (55%), and specifically in 251/556 melanomas (45%) evaluated with IHC, in 208/250 cases (83%) examined with soluble methods and in 13/23 melanoma lesions (57%) tested with polymerase chain reaction. Despite the correlation with parameters indicating an aggressive behavior, no studies demonstrated any prognostic value of HLA-G expression. Furthermore, uveal melanomas were constantly negative for this biomarker.
Overall, published data indicate that while HLA-G is involved in the interactions between melanomas and the immune system, it is unlikely to be the only factor to play such a role, therefore making it difficult to designate it as a prognostically relevant molecule. Evidence further suggests that HLA-G is not implicated in the immunobiology of uveal melanomas.
A systematic search was carried out in electronic databases. Studies dealing with HLA-G expression in surgically-removed human samples were retrieved and analyzed.
Of 1737 retrieved articles, 16 were included. The main themes regarded HLA-G expression in malignant melanocytic lesions, assessed by immunohistochemistry (IHC), soluble or molecular techniques, and its relationship with clinicopathological features, such as tumor thickness and malignant behavior. Overall significant HLA-G expression was found in 460/843 tumors (55%), and specifically in 251/556 melanomas (45%) evaluated with IHC, in 208/250 cases (83%) examined with soluble methods and in 13/23 melanoma lesions (57%) tested with polymerase chain reaction. Despite the correlation with parameters indicating an aggressive behavior, no studies demonstrated any prognostic value of HLA-G expression. Furthermore, uveal melanomas were constantly negative for this biomarker.
Overall, published data indicate that while HLA-G is involved in the interactions between melanomas and the immune system, it is unlikely to be the only factor to play such a role, therefore making it difficult to designate it as a prognostically relevant molecule. Evidence further suggests that HLA-G is not implicated in the immunobiology of uveal melanomas.
摘要：
人类白细胞抗原G（HLA-G）是非经典的HLAI类分子，参与诱导胎儿-母体界面的耐受性和逃避肿瘤细胞的免疫应答。该研究的目的是回顾已发表的有关HLA-G在恶性黑色素瘤中的表达及其临床病理和预后相关的文献。
在电子数据库中进行了系统搜索。检索并分析涉及手术切除的人样品中HLA-G表达的研究。
在检索到的1737篇文章中,包括16个。主要主题是HLA-G在恶性黑素细胞病变中的表达，通过免疫组织化学（IHC）评估，可溶性或分子技术，及其与临床病理特征的关系，如肿瘤厚度和恶性行为。在460/843肿瘤中发现了整体显著的HLA-G表达（55％），特别是在IHC评估的251/556黑色素瘤（45％）中，208/250例（83％）用可溶性方法检查，13/23例黑色素瘤病变（57％）用聚合酶链反应检查。尽管与指示攻击行为的参数相关，没有研究证明HLA-G表达有任何预后价值.此外，葡萄膜黑色素瘤对该生物标志物始终呈阴性。
总的来说，发表的数据表明，虽然HLA-G参与黑素瘤和免疫系统之间的相互作用，它不太可能是发挥这种作用的唯一因素，因此，很难将其指定为预后相关的分子。证据进一步表明，HLA-G与葡萄膜黑素瘤的免疫生物学无关。
在电子数据库中进行了系统搜索。检索并分析涉及手术切除的人样品中HLA-G表达的研究。
在检索到的1737篇文章中,包括16个。主要主题是HLA-G在恶性黑素细胞病变中的表达，通过免疫组织化学（IHC）评估，可溶性或分子技术，及其与临床病理特征的关系，如肿瘤厚度和恶性行为。在460/843肿瘤中发现了整体显著的HLA-G表达（55％），特别是在IHC评估的251/556黑色素瘤（45％）中，208/250例（83％）用可溶性方法检查，13/23例黑色素瘤病变（57％）用聚合酶链反应检查。尽管与指示攻击行为的参数相关，没有研究证明HLA-G表达有任何预后价值.此外，葡萄膜黑色素瘤对该生物标志物始终呈阴性。
总的来说，发表的数据表明，虽然HLA-G参与黑素瘤和免疫系统之间的相互作用，它不太可能是发挥这种作用的唯一因素，因此，很难将其指定为预后相关的分子。证据进一步表明，HLA-G与葡萄膜黑素瘤的免疫生物学无关。
